Van beleggers
voor beleggers
desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?

Ontvang nu dagelijks onze kooptips!

word abonnee

FD: Fortune vindt Crucell topper

25 Posts
Pagina: «« 1 2 | Laatste | Omlaag ↓
  1. jokus 9 mei 2005 09:56

    Zopas een artikel gelezen van de beheerders van PRIVAK KBC Biotech fonds uit belgië. Er zat geen enkel bedrijf uit de benelux in hun portefeuille !!??
    "Omdat de schaarse aandelen hen niet kon bekoren"!!?? In Nederland geloven we niet in de mogelijkheden van Pharming, en Crucell vinden we te duur, omdat het bedrijf vooral een produktieplatvorm is !!??

    Ik denk dat Mhr.Devenijns en Mvr.Amerijckx van deze Privak toch eerst eens wat meer op onderzoek moeten gaan naar wat Pharming en Crucell te bieden hebben ! Wat een lullige en oppervlakkige verklaring van zulke mensen zeg??

    Al goed dat ik m'n geld niet in dit Kbc privak gestopt heb, zulke amateurs !!
  2. [verwijderd] 9 mei 2005 13:34
    Het bericht van Fortune:

    25 BREAKOUT COMPANIES 2005

    Crucell
    Technology: Cells for vaccine production
    Sector: Biotech
    Headquarters: Leiden, Holland
    Website: www.crucell.com

    If the deadly bird flu simmering in Southeast Asia boils up into a pandemic, demand for influenza vaccines will explode. So will Crucell's stock price. The company offers a line of human cells that's emerging as a key ingredient for making the vaccines. Currently vaccine production entails growing flu viruses in fertilized chicken eggs; the viruses are extracted, deactivated, and processed into flu shots. The eggs come from high-tech poultry farms that would be hard to expand fast. Boosting vaccine production with Crucell's methods would be relatively easy—its cells, in which flu viruses thrive, are kept in big vats called bioreactors that can be readily multiplied to expand capacity.
    Recently the U.S. government awarded $97 million to Sanofi Pasteur, the vaccine unit of Sanofi Aventis, to fund its transition to Crucell technology for making flu vaccines in the U.S. The process is also being used to develop vaccines for malaria, Ebola virus, and West Nile virus. Crucell is hawking its technology to make many other bioengineered medicines too. A raft of drugmakers, including GlaxoSmithKline and Roche, have licensed its "PER.C6" cells for that purpose. If enough customers follow suit, Crucell's investors won't have to wait for a flu pandemic to see the stock take off. — David Stipp

  3. [verwijderd] 9 mei 2005 14:41
    Ik heb het mooie FORTUNE ARTIKEL over CRUCELL al diverse malen gelezen! het blijft boeien! ...explode...so will Crucell's stock price.
    gr
    janh

    quote:

    WY schreef:

    Het bericht van Fortune:

    25 BREAKOUT COMPANIES 2005

    Crucell
    Technology: Cells for vaccine production
    Sector: Biotech
    Headquarters: Leiden, Holland
    Website: www.crucell.com

    If the deadly bird flu simmering in Southeast Asia boils up into a pandemic, demand for influenza vaccines will explode. So will Crucell's stock price. The company offers a line of human cells that's emerging as a key ingredient for making the vaccines. Currently vaccine production entails growing flu viruses in fertilized chicken eggs; the viruses are extracted, deactivated, and processed into flu shots. The eggs come from high-tech poultry farms that would be hard to expand fast. Boosting vaccine production with Crucell's methods would be relatively easy—its cells, in which flu viruses thrive, are kept in big vats called bioreactors that can be readily multiplied to expand capacity.
    Recently the U.S. government awarded $97 million to Sanofi Pasteur, the vaccine unit of Sanofi Aventis, to fund its transition to Crucell technology for making flu vaccines in the U.S. The process is also being used to develop vaccines for malaria, Ebola virus, and West Nile virus. Crucell is hawking its technology to make many other bioengineered medicines too. A raft of drugmakers, including GlaxoSmithKline and Roche, have licensed its "PER.C6" cells for that purpose. If enough customers follow suit, Crucell's investors won't have to wait for a flu pandemic to see the stock take off. — David Stipp

25 Posts
Pagina: «« 1 2 | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 913,25 -0,03%
EUR/USD 1,0870 +0,03%
FTSE 100 8.420,26 -0,22%
Germany40^ 18.716,50 -0,12%
Gold spot 2.415,21 0,00%
NY-Nasdaq Composite 16.685,97 -0,07%

Stijgers

Orange...
+6,35%
Recticel
+2,66%
UCB
+2,63%
Ageas
+1,82%
AB InBev
+1,44%

Dalers

AZELIS...
-11,71%
EVS
-9,06%
Umicore
-2,85%
D'IETE...
-2,31%
Aedifica
-1,77%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links